...
首页> 外文期刊>British Journal of Cancer >Combined surgery and chemotherapy for the treatment of primary gastrointestinal intermediate- or high-grade non-Hodgkin's lymphomas
【24h】

Combined surgery and chemotherapy for the treatment of primary gastrointestinal intermediate- or high-grade non-Hodgkin's lymphomas

机译:外科手术和化学疗法联合治疗原发性胃肠道中,高度非霍奇金淋巴瘤

获取原文

摘要

Fifty-five consecutive patients with primary gastrointestinal intermediate or high grade non-Hodgkin's lymphoma were analysed to assess the efficacy of chemotherapy following surgical tumour resection. Histological subtypes were high grade (n = 18), intermediate grade (n = 36) and unclassified (n = 1). The majority of patients had gastric presentation (71%) and localised disease (84%). Surgery consisted of radical resection in 25 patients (45%) and partial or palliative excision in the remaining cases (22 and 8 respectively). Four subjects died within 3 months of surgery, two patients refused adjuvant chemotherapy and 49 completed the postoperative chemotherapeutic programme. Chemotherapy included either Fi2/74 (adriamycin + vincristine + bleomycin + cyclophosphamide + prednisone) or Fi3/74 (adriamycin + VM26 + bleomycin + cyclophosphamide + prednisone). Excluding the group who underwent radical tumour resection, postoperative chemotherapy induced complete remission in 81% of the remaining 30 patients. The 10-year cause-specific survival for the 53 treated patients was 76% (median follow-up 58 months) with a stable curve plateau after 80 months. Proportional-hazard multivariate statistics showed that survival was influenced by type of surgical resection (P less than 0.05) and stage (P less than 0.05), whereas age, sex and histological subtype were not influential. Our data indicate that chemotherapy following surgical resection of gastrointestinal lesion induces long-term remission in primary gastrointestinal lymphomas.
机译:分析了55例连续的原发性胃肠道中级或高级别非霍奇金淋巴瘤患者,以评估手术切除肿瘤后化疗的疗效。组织学亚型为高等级(n = 18),中等级(n = 36)和未分类(n = 1)。大多数患者有胃部表现(71%)和局部疾病(84%)。手术包括25例(45%)的根治性切除,其余病例(分别为22和8例)的部分或姑息性切除。 4名受试者在手术后3个月内死亡,两名患者拒绝辅助化疗,其中49名患者完成了术后化疗方案。化学疗法包括Fi2 / 74(阿霉素+长春新碱+博来霉素+环磷酰胺+泼尼松)或Fi3 / 74(阿霉素+ VM26 +博来霉素+环磷酰胺+泼尼松)。除接受根治性肿瘤切除的组外,其余30例患者中有81%术后化疗导致完全缓解。 53例接受治疗的患者的10年特定病因生存率为76%(中位随访58个月),在80个月后具有稳定的曲线平稳期。比例风险多元统计数据表明,手术切除类型(P小于0.05)和分期(P小于0.05)影响生存期,而年龄,性别和组织学亚型则无影响。我们的数据表明,手术切除胃肠道病变后的化学疗法可诱发原发性胃肠道淋巴瘤的长期缓解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号